Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Imatinib for LAM
Recruiting0 awardsPhase 1
New York, New York
This trial focuses on a rare lung disease called Lymphangioleiomyomatosis (LAM) that behaves like a slowly growing cancer. A study called MILES found that a drug called si
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service